Business Wire
Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing
📈
AI Sentiment
Highly Positive
10/10
- Home
- WGS
as of 03-18-2026 1:56pm EST
$71.89
$3.61
-4.78%
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
| Founded: | 2017 | Country: | United States |
| Employees: | 1300 | City: | STAMFORD |
| Market Cap: | 2.6B | IPO Year: | N/A |
| Target Price: | $140.71 | AVG Volume (30 days): | 684.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $55.17 - $170.87 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 29.98% | Revenue Growth (next year): | 24.85% |
| P/E Ratio: | 1251.58 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered WGS Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 18 hours ago
AI Recommendation
hold
Model Accuracy: 77.44%
77.44%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest GeneDx Holdings Corp. News
WGS Breaking Stock News: Dive into WGS Ticker-Specific Updates for Smart Investing
Zacks
WGS, Zevra Partner to Launch Genetic Testing for Niemann-Pick Type C
📊
AI Sentiment
Positive
6/10
Simply Wall St.
Can Zevra Therapeutics (ZVRA) Turn NPC Genetic Testing Access Into a Durable Rare-Disease Edge?
📊
AI Sentiment
Positive
7/10
Compare WGS vs Leading Stocks
See how WGS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "WGS GeneDx Holdings Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.